BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
Recruiting · NCT07151690 · Registry updated 2026-07-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis | Systemic Light Chain Amyloidosis | Recruiting | Phase 2 | 2026-07-23 | NCT07151690 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 285 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences | Tianjin | China | 2 |